Synthesis, cytotoxicity, and DNA-topoisomerase inhibitory activity of new asymmetric ureas and thioureas

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 2, 2006, Pages 492-499

  Esteves Souza, Andressa ^a   Pissinate, Kenia ^a   Graça Nascimento, Maria Da ^b   Grynberg, Noema Faiga ^a   Echevarria, Aurea ^a  

^a FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Cytotoxicity; DNA topoisomerase; Ureas and thioureas

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; N (3,3 DIPHENYLPROPYL) N (3,4 METHYLENODIOXYBENZYL) N' PHENYLTHIOUREA; N (3,3 DIPHENYLPROPYL) N (3,4 METHYLENODIOXYBENZYL) N' PHENYLUREA; N (3,3 DIPHENYLPROPYL) N (4 BROMOBENZYL) N' PHENYLTHIOUREA; N (3,3 DIPHENYLPROPYL) N (4 BROMOBENZYL) N' PHENYLUREA; N (3,3 DIPHENYLPROPYL) N (4 CYANOBENZYL) N' PHENYLTHIOUREA; N (3,3 DIPHENYLPROPYL) N (4 CYANOBENZYL) N' PHENYLUREA; N (3,3 DIPHENYLPROPYL) N (4 DIMETHYLAMINOBENZYL) N' PHENYLUREA; N (3,3 DIPHENYLPROPYL) N (4 METHYLBENZYL) N' PHENYLTHIOUREA; N (3,3 DIPHENYLPROPYL) N (4 METHYLBENZYL) N' PHENYLUREA; N (3,3 DIPHENYLPROPYL) N (4 NITROBENZYL) N' PHENYLTHIOUREA; N (3,3 DIPHENYLPROPYL) N (4 NITROBENZYL) N' PHENYLUREA; N (3,3 DIPHENYLPROPYL) N BENZYL N' PHENYLTHIOUREA; N (3,3 DIPHENYLPROPYL) N BENZYL N' PHENYLUREA; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; SPECTROPHOTOMETRY, INFRARED; THIOUREA; UREA;

EID: 28844447055     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.08.031     Document Type: Article

References (23)

1. J.C. Wang Annu. Rev. Biochem. 65 1996 635
2. Y. Pommier Biochimie 80 1998 255
3. M.R. Redinbo, L. Stewart, P. Kuhn, J.J. Champoux, and W.G.J. Hol Science 279 1998 504
4. A.Y. Chen, and L.F. Liu Annu. Rev. Pharmacol. Toxicol. 34 1994 191
5. U. Kellner, P. Rudolph, and R. Parwaresch Onkologie 23 2000 424
6. H.K. Wang, S.L. Morris-Natschke, and K.H. Lee Med. Res. Rev. 17 1997 367
7. P.R. Verma Bioorg. Med. Chem. 13 2005 1059
8. S.K. Singh, A.L. Ruchebman, T.K. Li, A. Liu, A.F. Liu, and E.J. Lavoie J. Med. Chem. 46 2003 2254
9. M.J. Gil, M.A. Mañú, C. Arteaga, M. Migliaccio, I. Encío, A. González, and V. Martínez-Merino Bioorg. Med. Chem. Lett. 9 1999 2321
10. J.W. Chern, Y.L. Leu, S.S. Wang, B. Jou, C.F. Lee, P.C. Tzou, S.C. Hsu, Y.C. Liaw, and H.M. Lin J. Med. Chem. 40 1997 227
11. E. Peticlerc, R.G. Deschesnes, M.F. Cote, C. Marques, R. Janvier, J. Lacroix, E. Miot-Noirault, J. Legault, E. Mounetou, J.C. Madelmont, and R. C-Gaudreault Cancer Res. 63 2004 4654
12. A.J. Olaharski, S.T. Mondrala, and D.A. Eastmond Mutant Res. 582 2005 79
13. J.D. Jiang, J. Roboz, I. Weisz, L. Deng, L. Ma, J.F. Holland, and J.G. Bekesi Anti-Cancer Drug Des. 13 1998 735
14. J. Easmon, G. Purstinger, G. Heinisch, T. Roth, H.H. Fiebig, W. Holzer, W. Jäger, M. Jenny, and J. Hofmann J. Med. Chem. 44 2001 2164
15. M. Miyahara, Y. Kashiwada, X. Guo, H.X. Chen, Y.C. Cheng, and K.H. Lee Heterocycles 39 1994 361
16. A.R. Katritzky, A. Oliferenko, A. Lomarka, and M. Karelson Bioorg. Med. Chem. Lett. 12 2002 3453
17. R.G. Wilde, and J.T. Billheimer Bioorg. Med. Chem. Lett. 5 1995 173
18. A. Esteves-Souza, A. Echevarria, C.M.R. Sant'Anna, and M.G. Nascimento Quím. Nova 27 2004 72
19. T. Mosmann J. Immunol. Methods 65 1983 55 63
20. Y.C. Martin Quantitative Drug Design: A Critical Introduction 1978 Marcel Dekker New York Vol. 8
21. A.J. Carpenter, and A.C.G. Porter Mol. Biol. Cell 15 2004 5700
22. P. Ackerman, C.V. Glover, and N. Osheroff Proc. Natl. Acad. Sci. U.S.A. 82 1985 3164
23. A.K. Larsen, A.E. Escargueil, and A. Skladanwski Pharmacol. Ther. 99 2003 167